In this episode, Georgios Gakis, MD, and Mario Wolfgang Kramer, MD, PhD, discuss key data on immune checkpoint inhibitors for urothelial carcinoma informing their clinical practice in Germany. Topics include:

• Guideline changes for first-line UC based on data from JAVELIN Bladder 100 trial on avelumab maintenance after chemotherapy
• Results from IMvigor130 and KEYNOTE-361 trials on concurrent immune checkpoint inhibition plus chemotherapy
• When to consider first-line treatment with immune checkpoint inhibitor monotherapy
• Utility of PD-L1 as biomarker for immune checkpoint inhibitor–based therapy

Presenters:

Georgios Gakis, MD  
Professor of Urology, Staff Urologist
University Hospital of Würzburg  
Würzburg, Germany

Mario Wolfgang Kramer, MD, PhD  
Consultant Urologist
Vice Director, Urology
University Hospital Schlewig-Holstein Campus Lübeck
Lübeck, Germany

Content based on an online IME program supported by an educational grant from Pfizer and EMD Serono, Inc.

Link to full program, including associated downloadable slidesets and on-demand webcast:
https://bit.ly/3kJC5SL

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.